Chanticleer holdings announces merger agreement with sonnet biotherapeutics

Chanticleer holdings announces merger agreement with sonnet biotherapeutics to advance pipeline of novel immune therapeutics.chanticleer holdings inc - chanticleer to spin-off existing operations -.chanticleer holdings inc - strategic expansion of sonnet's proprietary platform.chanticleer holdings inc - initiation of two new clinical programs expected in 2020.chanticleer holdings inc - sonnet will become majority owners of chanticleer's outstanding common stock.chanticleer holdings inc - former sonnet shareholders will hold about 94% of outstanding shares of combined co.chanticleer holdings inc - proposed merger will result in a publicly-traded company operating under sonnet name.chanticleer holdings inc - terms of merger include a payment of $6 million to chanticleer from sonnet.chanticleer holdings inc - chanticleer will change its name to sonnet biotherapeutics holdings, inc..chanticleer holdings inc - proposed merger will result in proposed co under nasdaq ticker symbol "sonn".chanticleer holdings inc - chanticleer will spin-off its current restaurant operations into a newly created entity.chanticleer holdings inc - pankaj mohan will serve as chairman and chief executive officer of merged co.chanticleer holdings - spin-off entity will receive 5 year warrant to purchase about 2% of co's shares at deal close time at $0.01 per share.
SONN Ratings Summary
SONN Quant Ranking